Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation-Reference-Cited by-同舟云学术

Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation

Published:2005-06-01 Issue:11 Volume:11 Page:4182-4190
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Antonescu Cristina R.,Besmer Peter,Guo Tianhua,Arkun Knarik,Hom Glory,Koryotowski Beata,Leversha Margaret A.,Jeffrey Philip D.,Desantis Diann,Singer Samuel,Brennan Murray F.,Maki Robert G.,DeMatteo Ronald P.

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 704 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fibroblast Growth Factor 2 (FGF2) Activates Vascular Endothelial Growth Factor (VEGF) Signaling in Gastrointestinal Stromal Tumors (GIST): An Autocrine Mechanism Contributing to Imatinib Mesylate (IM) Resistance;Cancers;2024-09-07

2. The INSIGHT study: a randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with KIT exon 11 + 17/18 mutations;Future Oncology;2024-09-04

3. Molecular Profiling of KIT/PDGFRA-Mutant and Wild-Type Gastrointestinal Stromal Tumors (GISTs) with Clinicopathological Correlation: An 18-Year Experience at a Tertiary Center in Kuwait;Cancers;2024-08-21

4. Entry of ZSWIM4 to the nucleus is crucial for its inhibition of KIT and BMAL1 in gastrointestinal stromal tumors;Cell & Bioscience;2024-06-29

5. A PDE3A-SLFN12 Molecular Glue Exhibits Significant Antitumor Activity in TKI-Resistant Gastrointestinal Stromal Tumors;Clinical Cancer Research;2024-06-12